1 Effect of neonatal BCG vaccination on the evolution of Hashimoto's Thyroiditis

2

- Kanhaiya Agrawal, Preetam Basak, Darshan Badal, Pinaki Dutta, Rama Walia, Naresh
 Sachdeva.
- 5 Department of Endocrinology, Post Graduate Institute of Medical Education and Research,
- 6 Chandigarh, India.

7

8 Corresponding Author:

- 9
- 10 Prof. Naresh Sachdeva
- 11 Department of Endocrinology
- 12 Post Graduate Institute of Medical Education and Research (PGIMER)
- 13 Chandigarh, INDIA
- 14 Phone: +91-172-2755282, +91-8437508280
- 15 E mail: sachdeva.naresh@pgimer.edu.in
- 16

18 ABSTRACT

Background: Hashimoto's thyroiditis (HT) involves the autoimmune destruction of thyrocytes with the presence of anti-thyroid peroxidase (TPO) and/or anti-thyroglobulin (TG) antibodies. In autoimmune diseases, an immunomodulatory role of Bacillus Calmette-Guerin (BCG) vaccination has been reported with decreased autoantibody production and induction of regulatory T cells. We hypothesize that a decline in the efficacy of BCG might be associated with the appearance of HT during adulthood.

25 Methods: Adult subjects with subclinical HT (HT-SCH) (n=39) and non-autoimmune 26 subclinical hypothyroidism (NA-SCH) (n=25) were enrolled along with euthyroid healthy 27 controls (HC) (n=20). The BCG-specific immune responses were determined by the Mantoux test and BCG-induced in-vitro proliferation of peripheral blood mononuclear cells (PBMC). 28 29 Anti-thyroid cellular immune responses were assessed in subjects with human leukocyte 30 antigen (HLA)-A*02 and HLA-A*24 alleles by determining the frequency of CD8+ T cells recognizing major histocompatibility complex (MHC) dextramers (DMR) carrying TPO-31 32 derived peptides, by flow cytometry.

33 **Results:** The HT-SCH group had a lower rate of Mantoux test reactivity (38.5%) as 34 compared to NA-SCH (64%) and HC subjects (65%) (p=0.047). However, the BCG-induced 35 in-vitro proliferation of PBMC was similar in HT-SCH, NA-SCH, and HC groups. Further, 36 the BCG-vaccinated SCH subjects had lower levels of thyroid stimulating hormone (TSH) 37 (p=0.026). Next, the SCH subjects had higher frequencies of peripheral DMR+ CD8+ T cells 38 as compared to HC subjects (p=0.001). Interestingly, the frequency of peripheral DMR+ 39 CD8+ T cells was significantly higher in HT-SCH than HC subjects (p=0.045). Finally, we 40 observed a positive correlation between the frequency of DMR+CD8+ T cells and TSH levels 41 (r = +0.620, p=0.006).

42 **Conclusions:** Collectively, our results highlight a complex relationship of neonatal BCG 43 vaccination with the genesis of HT, via modulation of autoimmune responses directed 44 towards thyroid autoantigens.

Keywords: Subclinical hypothyroidism, Autoimmune thyroid disease, BCG vaccine,
Thyroid peroxidase (TPO), Autoreactive CD8+ T cells.

47

48 Authors' Contributions

KA collected and processed all blood samples, performed all the experiments, managed the patients, collected and interpreted the data, and wrote the manuscript. **PB** assisted in performing the experiments. **DB** helped in FACS analysis and determination of TPO peptides. **PD** and **RW** helped in design of study, recruited and supervised the patient selection and management. **NS** conceptualized and designed the study, supervised the experiments and edited the manuscript.

56	Abbreviation	15:
57	APC	Allophycocyanin
58	BCG	Bacillus Calmette–Guérin
59	CFSE	Carboxyfluorescein diacetate succinimidyl ester
60	DMR	Dextramer
61	7-AAD	7-aminoactinomycin D
62	FITC	Fluorescein isothiocyanate
63	FMO	fluorescence minus one
64	FNAC	Fine needle aspiration cytology
65	HC	Healthy control
66	HIV	Human immunodeficiency virus
67	HLA	Human leukocyte antigen
68	HT	Hashimoto's thyroiditis
69	IEDB	Immune epitope database
70	MHC	Major histocompatibility complex
71	MS	Multiple sclerosis
72	MTB	Mycobacterium tuberculosis
73	NA-SCH	Non-autoimmune subclinical hypothyroid
74	PBMC	Peripheral blood mononuclear cells
75	PCR	Polymerase chain reaction
76	PerCP	Peridinin-chlorophyll
77	PPD	Purified protein derivative
78	RPMI	Roswell Park Memorial Institute
79	SCH	Sub-clinical hypothyroidism
80	SD	Standard deviation
81	T1D	Type-1 diabetes
82	T3	Triiodothyronine
83	T4	Thyroxine
84	TG	Anti-thyroglobulin
85	TPO	Anti-thyroid peroxidase
86	Tregs	Regulatory T cells
87	TSH	Thyroid stimulating hormone
88	TU	Tuberculin units
89		

90 **INTRODUCTION**

Hashimoto's thyroiditis (HT) is an autoimmune disorder of the thyroid gland characterized by
lymphocytic infiltration and destruction of thyrocytes. The prevalence of HT varies from 510% and is on the rise, with female preponderance and advancing age [1–4]. The initial
pathogenesis of HT involves underlying genetic susceptibility and an environmental trigger
like infection, stress, etc., and is seen commonly in iodine-sufficient areas [5]. Various genes
implicated in the pathogenesis of HT include human leucocyte antigen (HLA-DR3, HLA-A2,

HLA-A24), cytotoxic T lymphocyte-associated protein-4 (CTLA-4), and protein tyrosine
phosphatase-22 (PTPN22), etc. [6,7]. Further, there is systemic interaction between T cells,
antigen-presenting cells (APCs), and thyroid cells [8,9]. The pathological changes in HT
appear with lymphocytic infiltration causing gradual destruction of thyroid follicles, followed
by the replacement of thyroid parenchyma with fibrous tissue labeled as atrophic thyroiditis
[10].

103 Bacillus Calmette Guérin (BCG) vaccine is administered during the neonatal stage in countries where tuberculosis (TB) is endemic. BCG has a protective effect against 104 105 disseminated TB and meningitis in children, however, in adults, the immunoprotection 106 against pulmonary TB declines due to a gradual loss in its efficacy [11,12]. In addition, an 107 immunomodulatory role of BCG associated with a decrease in autoantibodies, and induction 108 of regulatory T cells (Tregs) has been suggested [13]. BCG has also been shown to halt the 109 pathogenesis of other autoimmune diseases, type-1 diabetes (T1D) and multiple sclerosis 110 (MS) by promoting the apoptosis of activated CD4+T cells [14–17]. Since HT is a manifestation that appears mainly in adulthood, it could be possible that loss of efficacy of 111 112 BCG might be associated with the appearance of thyroiditis. In a previous report, the BCG vaccine did not prevent the pathogenic initiation of autoimmunity against thyroid-stimulating 113 114 hormone Receptor (TSHR) but halted the progression to Graves' disease [18,19]. However, 115 the exact mechanisms behind this immunomodulation are still elusive. To date, there is no 116 definitive evidence in humans on the protective or therapeutic effects of BCG in HT. In this 117 direction, our study is aimed to understand, whether, the onset of HT is associated with a 118 decline in the efficacy of BCG vaccination. Here, we assessed BCG-specific immune 119 responses in the context of anti-thyroid autoimmune responses in recently diagnosed 120 subclinical HT in comparison to non-autoimmune subclinical hypothyroid (NA-SCH) and 121 euthyroid healthy control (HC) subjects.

This article was previously presented as a meeting abstract at the Annual Endocrine Society
Conference (Virtual), March 2021 (Session: Thyroid Autoimmunity, COVID-19 & Thyroid
Disease. Abstract Number: 7318).

125

126 MATERIALS AND METHODS

127 Research design and recruitment of subjects

A total of 84 subjects, aged 18-60 years, presenting with sub-clinical hypothyroidism (SCH) 128 129 (n=64) and euthyroid normal healthy controls (HC) (n=20) attending departments of 130 Endocrinology at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India were enrolled from Oct 2019 to Jan 2021. The SCH subjects were further 131 divided into Hashimoto's thyroiditis (HT-SCH) (n=39) and non-autoimmune (NA-SCH) 132 133 (n=25) groups based on the presence of anti-thyroid antibodies. After obtaining informed 134 consent, subjects were screened for TSH, thyroxine (T4), triiodothyronine (T3), free T4, free 135 T3, thyroglobulin (TG), anti-thyroperoxidase (anti-TPO), anti-thyroglobulin (anti-TG) and

136 TSH receptor antibody titers. The criterion for inclusion of SCH subjects was; TSH levels 137 between 4.2-10.0 μ IU/ml with normal fT4 levels. Subjects with prior levothyroxine 138 treatment, symptomatic hypothyroidism, infertility, pregnancy or planning for pregnancy, 139 immune deficiency, diabetes mellitus, human immunodeficiency virus (HIV) infection, 140 chronic steroid or immunosuppressant medication, concurrent or past chemotherapy or 141 radiotherapy, active or past tuberculosis, malignancy, and hepatic, renal or cardiac failure 142 were excluded. The study was approved by the institutional ethics committee.

The persistence of the efficacy of BCG vaccination was measured primarily in terms of response to the Mantoux test, and secondly by the presence of a scar formed during primary vaccination (BCG scar). Each subject's arms and legs were examined for the presence of a BCG scar. For the Mantoux test, 0.1 ml of five tuberculin units (TU) of purified protein derivative (PPD) solution was injected intra-dermally on the volar surface of the upper third region of the forearm by an expert vaccinator in all subjects and examined after 48 hours for induration.

150

151 Peripheral blood mononuclear cell (PBMC) isolation and in-vitro culture with BCG

A total of 10⁶ PBMCs/ml labeled with carboxyfluorescein diacetate succinimidyl ester 152 (CFSE) (5 mM) were plated in triplicates in flat bottom 24-well tissue culture plates (BD-153 Falcon, USA) in Roswell Park Memorial Institute medium (RPMI)-1640 medium 154 supplemented with 0.1% penicillin, streptomycin, 10% fetal calf serum and stimulated with 155 optimized concentration of 30µl BCG (2-8 x 10⁶ bacilli/ml) (Serum institute, India) or 2µl 156 antiCD3, anti-CD28 DynabeadsTM (Invitrogen, USA) (positive control) or without any 157 158 stimulant (negative control) for 96 h at 37 °C in 5% CO2 [20,21]. Post culture, the cells were centrifuged at 200g for 10 minutes, acquired on a flow cytometer (FACS Lyric), and 159 160 analyzed using FACS Suite (version 1.3) software (BD Biosciences, USA). At least 10000 events were acquired and proliferation indices were calculated as described previously [22]. 161

162 HLA typing of subjects

DNA was extracted from a 1.0 ml buffy coat of blood samples using QIAampTM DNA Blood Mini Kit (Qiagen, Hiden, Germany). HLA typing of the recruited subjects was carried out by sequence-specific primers-polymerase chain reaction (PCR-SSP) method (Olerup, Stockholm, Sweden). The PCR products were resolved on a 2% agarose gel. HLA type was interpreted using the SCORETM software (Olerup, Stockholm, Sweden).

168 Dextramer synthesis and validation

HLA class I alleles (A*02, A*24) were selected for the synthesis of peptide dextramers
(DMR) as these alleles have a higher affinity for auto-antigenic thyroid peptides and
contribute to the development of HT [6]. Two different allophycocyanin (APC) labeled
MHC-I DMRs loaded with 8-11mer TPO-derived peptides (A*0201/ALARWLPV,

A*2402/VFSTAARF) having the highest cumulative affinity, as determined by MHC-I
peptide binding prediction software, Bioinformatics and Molecular Analysis Section
(BIMAS), (Centre for Information Technology, NIH, USA), SYFPEITHI (Biomedical
Informatics, Heidelberg, Germany) and T cell Epitope Prediction Tool of Immune Epitope
Database (IEDB) (La Jolla, CA) were custom synthesized (Immudex, Denmark).

178 Immunophenotyping and analysis of TPO-specific CD8+ T cells

179 The frequencies of TPO-dextramer (DMR) recognizing CD8+ T cells were measured to 180 assess the degree of cellular immune responses against the thyroid gland. After determining 181 HLA-I type, a fresh sample of heparinized peripheral blood was obtained from 14 SCH and 4 182 HC subjects for immunophenotyping. PBMCs were isolated by density gradient 183 centrifugation with Ficoll (Sigma, USA). After checking cell viability by 7-amino 184 actinomycin D (7-AAD) exclusion, TPO-specific CD8+ T cells were stained by incubating 2 $\times 10^{6}$ PBMCs with 10 µl of respective DMRs at room temperature in the dark for 10 min. 185 Anti-CD3 peridinin-chlorophyll (PerCP), anti-CD8 Alexa-fluor 700, and anti-CD4 186 fluorescein isothiocyanate (FITC) antibodies were then added with 15 min incubation, 187 followed by washing with FACSTM buffer (BD Biosciences, USA). The stained cells were 188 acquired on a flow cytometer (FACS Lyric) and analyzed using FACS Suite (version 1.3) 189 190 software (BD Biosciences, USA). At least one million total events were acquired and a 191 minimum of 500,000 T cells were analyzed. Gating was first performed on lymphocytes 192 followed by gating of CD3+ CD4+ CD8+ cells to exclude CD3- T cells, monocytes, NK 193 cells, and B cells. CD8+ T cells recognizing the DMRs were then gated and analyzed. 194 Relevant fluorescence minus one (FMO) tubes were used to set gates.

195 Statistical Analysis

Statistical analyses were performed using Statistical Package for The Social Sciences (SPSS 196 v22.0) (SPSS Inc., Chicago, IL). Continuous variable data was expressed as mean± Standard 197 198 Deviation (SD) or median with inter-quartile range (1st - 3rd) and discrete variables as 199 proportions. The student's t-test or one-way analysis of variance (ANOVA) was used to 200 compare the difference between means of normally distributed variables, while Mann 201 Whitney or Kruskal Wallis was used to compare the difference between means of variable 202 with inequality of variance. The chi-square test or Fischer exact was used to examine the 203 difference between proportions. Comparison between the three groups was done using Tukey 204 post hoc analysis. The Pearson correlation coefficient was used for the correlation of 205 parametric data, whereas Spearman correlation analysis was performed for non-parametric data. All comparisons were done at a level of significance of 0.05. 206

207

209 **RESULTS**

210 Clinical characteristics of the study subjects

Of the total 64 subclinical hypothyroid subjects, 39 subjects had subclinical Hashimoto's thyroiditis (HT-SCH), 25 subjects had non-autoimmune SCH (NA-SCH) and 20 subjects were non-autoimmune euthyroid healthy controls (HC). The clinical and biochemical characteristics including TSH, T4, T3, fT4, and fT3 are documented in Table 1. The thyroid profile was repeated for all subjects at 6 months as a part of regular work-up and the intrasubject thyroid profile and anti-thyroid antibody status was similar at both time points. Other biochemical characteristics of the subjects are shown in Table 2.

Table 1: Clinical and biochemical characteristics of HT-SCH, NA-SCH and HC subjects.

Variables	HT-SCH (n=39)	NA-SCH (n=25)	HC (n=20)	P-value
Age (years)*	37.64±11.5	34.92 ±10.3	33.5±8.02	0.313
Sex (Female), n (%)	33 (84.6)	16 (64)	16 (80)	0.149
BMI (kg/m ²)	25.8±4.65	25.4±7.09	25.66±3.20	0.944
BCG scar, Present, n (%)	34 (87.18)	19 (76)	19 (95)	0.182
TSH (µIU/ml)*	7.0±1.7	6.8±1.51	2.3±0.66	0.001+
fT4 (ng/dl)*	1.34±0.35	1.43±0.41	1.22±0.33	0.124
fT3 (pmol/L)*	5.39±0.94	5.87±1.15	5.45±0.42	0.159
Anti TG Ab (IU/ml) [#]	72.5 (11.7-59.6)	5 (5-9.8)	5 (5-9.0)	0.001++
Anti-TPO Ab (IU/ml) [#]	294.6 (120.2- 764.2)	26.4 (14.1- 47.44)	10 (10-14.3)	0.001++

* Mean (±SD), P-value was calculated by one-way ANOVA test for parametric data, # 220 Median (1st - 3rd quartile), P-value was calculated by Kruskal Wallis test for continuous non-221 222 parametric data and Chi-square test for categorical data. Abbreviations: HT-SCH Subclinical 223 Hashimoto's thyroiditis, NA-SCH: Non-autoimmune subclinical hypothyroidism, HC: 224 Healthy control, BMI: Body mass index, BCG: Bacillus Calmette-Guerin, TSH: Thyroid 225 stimulating hormone, fT4: Free thyroxine, fT3: Free triiodothyronine, TG: Thyroglobulin, 226 TPO: Thyroid peroxidase, Ab: Antibody; (+) p-value between HT-SCH and NA-SCH vs. 227 HC, (++) p-value between HT-SCH vs. HC and NA-SCH subjects

228

230 Table 2: Other biochemical characteristics of HT-SCH, NA-SCH and HC subjects

Variables	HT-SCH (n=39)	NA-SCH (n = 25)	HC (n = 20)	P-value
Family History of Hypothyroidism, Present, n (%)	12 (31%)	4 (16%)	5 (25%)	0.390
Thyroglobulin (ng/ml)	8.95 (1.7- 43.22)	16.65 (7.63- 25.0)	16.7 (11.5- 22.1)	0.413
$CRP (mg/L)^{\#} (Normal=0-6)$	2.44 (0.87-5.2)	3.12 (1.9-5.6)	3.1 (1-5.5)	0.810
Vitamin B12 (pg./ml) [#]	219.7 (144- 360)	215 (125.8-391)	256 (155-449)	0.638
Iron deficiency, n (%)	16 (41%)	10 (40%)	6 (28.6%)	0.653
Vitamin D (ng/ml) [#]	15.7 (9.9-22.9)	16.23 (10-24.7)	12 (7-20.1)	0.328
Total cholesterol (mg/dl)*	169.13±27.45	174.97±41.36	150.46±27.13	0.043+
LDL (mg/dl)*	106.61±24.67	109.38±36.40	88.94±25.56	0.056
HDL (mg/dl)*	45.43±11.91	51.07±9.26	45.03±8.84	0.234
Triglyceride (mg/dl)*	129.13±63.93	116.82±56.53	124.21±51.22	0.749
Hemoglobin (g/dl)*	12.24±1.30	12.35±1.9	12.49±1.37	0.819
Urea (mg/dl)*	20.64±6.36	21.86±5.46	18.64±6.8	0.157
Uric acid (mg/dl)*	4.44±1.09	4.69±1.07	3.69±1.3	0.705
Creatinine (mg/dl)*	0.74±0.24	0.74±0.15	0.68±0.19	0.467
Total protein (g/dl)*	7.52±0.44	7.55±0.57	7.53±0.52	0.979
Albumin (g/dl)*	4.46±0.33	4.51±0.41	4.33±0.37	0.174
Bilirubin (mg/dl)*	0.57±0.25	0.60±0.26	0.73±0.27	0.066
ALP (U/L) *	94.47±40.5	89.48±21.19	81.45±22.93	0.313
AST (U/L)*	27.35±7.48	25.97±14.69	27.6±8.8	0.852
ALT (U/L)*	28.53±14.63	31.90±27.59	27.65±17.51	0.723

* Mean(±SD), P-value was calculated by one-way ANOVA test for parametric data, #
Median (1st - 3rd quartile), P-value was calculated by Kruskal Wallis test for continuous nonparametric data, and Chi-square test for categorical data. (+) p-value between NA-SCH and
HC subjects. Abbreviations: HT-SCH Subclinical Hashimoto's thyroiditis, NA-SCH: Nonautoimmune subclinical hypothyroidism, HC: Healthy control, CRP: C-reactive protein,
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, ALP: Alkaline phosphatase,
AST: aspartate aminotransferase, ALT: Alanine transaminase.

238 Assessment of efficacy of primary BCG vaccination

The efficacy of primary (neonatal) BCG vaccination was determined by Mantoux test 239 240 reactivity and by in-vitro proliferative responses of peripheral blood lymphocytes to BCG. The Mantoux test-associated induration was observed in fewer HT-SCH subjects (induration 241 diameter \geq 5mm) (38.5%) as compared to NA-SCH (64%) and HC (65%) subjects (p=0.047) 242 243 (Figure 1) (Table 3), with odds ratio (OR) between HT-SCH versus HC and NA-SCH subjects being, 0.34 (0.11-1.0, p=0.05) and 0.35 (0.12-0.99, p=0.046), respectively. Secondly, 244 245 the peripheral blood mononuclear cells were isolated from the subjects and cultured in the 246 presence of BCG vaccine (Figure 2). In contrast to the Mantoux test, the in-vitro lymphocyte proliferation in the presence of BCG was similar in HT-SCH and NA-SCH subjects 247 (proliferation index, 2.55±0.31 vs. 2.51±0.41, p=0.889). 248

Figure 1: Representative image of induration at forearm, after 48 hours of Mantoux test.



251

- **Legend:** An inducation diameter < 5mm was considered as non-reactive.
- 253


Table 3: Mantoux test response and BCG-induced *in vitro* lymphocyte proliferation in HT-SCH, NA-SCH and HC subjects

Outcome va	riables	HT-SCH	NA-SCH	HC (n=20)	P-value
		(n=39)	(n=25)		
Mantoux	Positive, n (%)	15 (38.5)	16 (64)	13 (65)	0.047+

Test	Negative, n (%)	24 (61.5)	09 (36)	07 (35)	
Proliferation index (BCG)*		2.55±0.31	2.51±0.41	2.46±0.29	0.667
Proliferation	index (anti-	2.59±0.26	2.53±0.39	2.44±0.26	0.285
CD3/CD28) *	*				
Proliferation	index (MC)*	2.51±0.28	2.44±0.38	2.40±0.27	0.677

* Mean(±SD) p-value was calculated by independent-samples t-test for parametric data and
chi-square test for categorical variables. (+) p-value between HT-SCH vs. NA-SCH and HC
subjects. Abbreviations: HT-SCH: subclinical Hashimoto's thyroiditis, NA-SCH: nonautoimmune subclinical hypothyroidism, HC: healthy control, BCG: Bacillus CalmetteGuerin, CD: cluster of differentiation, MC: Media control.

Figure 2: Representative flow-cytograms showing proliferation of CFSE labelled peripheral blood mononuclear cells (PBMC) isolated from the peripheral blood of a subject with subclinical Hashimoto's thyroiditis (HT-SCH).





Legend: The PBMCs were labeled with CFSE (5mM) at RT for 20 min then stimulated in-vitro with BCG or anti-CD3, anti-CD28 Dynabeads for 96 hours and analyzed on a flow

cytometer. P2 represents the parent population, whereas P3-P8 represent the daughter
population after consecutive divisions. a) Lymphocytes were gated as per forward and side
scatter profiles. The proliferation of CFSE labeled lymphocytes in, b) unstimulated cultures
(negative control, MC), (c), in the presence of anti-CD3, anti-CD28 DynabeadsTM (positive
control), and (d), in the presence of BCG (30 µl/well).

273


274 Assessment of autoimmune responses to thyroid antigens

As a measure of humoral autoimmunity towards the thyroid gland, we assessed the titers of anti-TPO, anti-TG, and anti-TSHR antibodies in all subjects. Amongst the SCH group, anti-TPO, anti-TG, and both (anti-TPO and anti-TG) antibodies were positive in 64%, 77%, and 41% of subjects respectively. The levels of anti-TSHR antibodies were low and well below the cut-off limit (<0.8 IU/L) in all three groups, indicating the absence of humoral immune responses toward TSHR.

281 To determine the HLA-specific cellular immune responses toward the thyroid gland, we 282 performed HLA-typing of the subjects and chose TPO as the target antigen. At first, we 283 observed heterogeneity of HLA-I alleles in our study subjects. HLA typing was performed in 284 52/84 subjects, including 41 SCH and 11 healthy controls. In the case of MHC-I, HLA-A*24 285 (41%) was the most frequent allele in SCH subjects followed by HLA-B*07 (37%) and HLA-286 A*01 (31%). HLA-A*02 was seen in 27% of subjects of SCH. In the case of MHC class II, 287 the most frequent allele was HLA-DQB1*02 (78%) followed by HLA-DRB1*01 (65%) 288 (Figure 3). Based on the frequency of HLA-I alleles, we assessed the frequency of peripheral CD8+ T cells that bind to TPO-derived epitopes using MHC-I dextramers. These autoreactive 289 290 cells were termed DMR+ CD8+ T cells and analyzed by flow cytometry (Figure 4).

²⁹¹

Figure 3: HLA alleles of the study subjects.




Legend: a: A representative agarose gel image of PCR amplified products during molecular HLA typing (PCR-SSP), showing the internal control band, amplified allele band and negative control. Lane 1 represents negative control. The amplified internal control is present in all the lanes except negative control. Amplified allele bands are observed in lanes 2, 5, 18, 38, 39, 55, 1, 62, 64, 65, 71, 80, 81, 82 and 86. HLA type of the subjects was determined using SCORETM software provided by the manufacturer (Olerup, Stockholm, Sweden). b: Frequency of various HLA I and HLA II alleles determined by molecular HLA typing in SCH subjects.

323 Figure 4: Representative images showing gating strategy for the immunophenotyping of

324 TPO-specific autoreactive CD8+ T (DMR+ CD8+ T cells) cells in the peripheral blood

325 from a HT-SCH subject.

326



Legend: a) Lymphocytes were gated as per forward and side scatter profiles, b) gating of
CD3+ T cells, c) gating of CD8+CD4- T cells in FMO tube, d) DMR+CD8+ T cells set in
FMO tube for negative control, e) gating of CD8+CD4- T cells and f) CD8+ T cells
recognizing DMRs carrying TPO derived peptide selected as DMR+ve cells.

We took HLA-A*02 and HLA-A*24 negative HT-SCH subjects as negative controls to determine the frequency of DMR+CD8+ T cells in SCH subjects in comparison to HC subjects as described previously [20]. The average frequency (%) of DMR+CD8+ T cells was

deducted from the frequency (%) of DMR+CD8+ T cells in HLA-A*02 and HLA-A*24 positive subjects to calculate the actual frequency (%) of autoreactive CD8+ T cells recognizing TPO epitopes. At first, to rule out whether the SCH subjects had higher frequency of peripheral CD8+ T cells, we calculated the CD4:CD8 T cell ratios and observed that HC and SCH subjects had similar CD4: CD8 T cell ratios (2.57 ± 1.1 vs. 2.06 ± 1.09 , p=0.438), Interestingly, we observed that the SCH subjects had higher frequencies of DMR+

342 CD8+ T cells ($7.6\pm4.46\%$ vs. $1.61\pm0.80\%$, p=0.001) as compared to healthy controls.

343 The calculated frequency (%) of DMR+ CD8+ T cells was found to be similar in NA-SCH

and HT-SCH subjects [mean (±SD) 6.6±4.33% vs. 9.02±4.17%, p=0.737]. As expected, the

345 DMR+ CD8+ T cells were significantly higher in HT-SCH than in HC subjects (9.02±4.17

346 vs. 1.61±0.80 %, p=0.045) (Table 4) (Figure 5).

Next, we observed a significant positive correlation between the frequency of DMR+CD8+ T cells and TSH levels (r=+0.620, p=0.006) in the complete cohort, indicating that the appearance of TPO-specific CD8+ T cells is associated with the onset of hypothyroid disease. However, there was no significant correlation between the frequency of DMR+CD8+ T cells and anti-TPO antibody titers (r=+0.207, p=0.409) or anti-TG antibody titers (r=+0.108, p=0.669).


Outcome variables	HT-SCH	NA-SCH	HC (n= 04)	P-value
	(n=09)	(n=05)		
CD3+ Lymphocytes (%)*	60.28±8.53	68.12±3.55	65.0±15.97	0.336
CD3+CD8+ T cells (%)*	18.47±7.32	21.67±6.43	21.17±14.90	0.723
CD3+CD4+ T cells (%)*	35.71±10.01	36.56±7.64	42.68±16.65	0.559
CD4: CD8 T cell ratio*	2.18±1.01	1.83±0.74	2.57±1.1	0.555
DMR +ve (CD8+ T cells) (%)*	9.02±4.17	6.6±4.33	1.61±0.80	0.045+

353 Table 4: Cellular autoimmune responses to thyroid antigens in SCH and HC subjects

* Mean (±SD), P value was calculated by one-way ANOVA test. (+), p-value between HT-SCH
vs. HC subjects. Abbreviations: HT-SCH: subclinical Hashimoto's thyroiditis, NA-SCH: nonautoimmune subclinical hypothyroidism, HC: healthy control, DMR: APC labelled MHC-I
Dextramers loaded with thyroid peroxidase (TPO) derived peptide, BCG: Bacillus CalmetteGuerin, CD: Cluster of differentiation.

360 Figure 5: Assessment of anti-thyroid autoreactive CD8+ T cell responses

361



362

Legend: a) Comparison of the mean relative frequency of DMR+ CD8+ T cells in the 363 364 peripheral blood of subclinical hypothyroid (SCH) and healthy control (HC) subjects. b) 365 Comparison of the mean relative frequency of DMR+CD8+ T cells in subclinical Hashimoto's thyroiditis (HT-SCH), non-autoimmune SCH (NA-SCH) subjects, and healthy 366 controls (HC). c) Correlation between TSH levels and DMR+CD8+ T cells (amongst CD8+ 367 368 T cells). Data is presented as mean±SD and Student's t-test was used to compare the means 369 in figure (a) whereas, one-way ANOVA followed by Tukey's multiple comparison test was used to compare the means in figure (b), and correlation is presented as Pearson coefficient in 370 figure (c). $P \square < \square 0.05$ was considered as statistically significant. 371

372 Comparison of SCH subjects based on BCG vaccination

The presence or absence of a scar at the site of BCG administration may suggest, whether the

- 374 subject has been vaccinated (Table 5). Overall, the TSH levels were significantly lower in
- 375 BCG-vaccinated subjects (presence of a BCG scar) (6.75±1.56 vs. 7.94±1.67 µIU/ml,
- p=0.026) as compared to non-BCG vaccinated subjects (absence of a BCG scar). The non-

BCG-vaccinated SCH subjects had a lower BMI (22.15±2.81 vs. 26.34±5.82, p=0.030) as compared to the BCG-vaccinated SCH subjects. Overall, the anti-mycobacterial response i.e.,

379 Mantoux test (induration in mm) was comparable in both the groups (p=0.663). Also, the

380 non-BCG vaccinated SCH subjects had similar in-vitro BCG-induced lymphocyte

proliferation response $(2.38\pm0.29 \text{ vs. } 2.56\pm0.36, \text{ p}=0.127)$ as compared to the BCG

382 vaccinated SCH subjects.

383	Table 5: Thyroid profile, anti-mycobacterial responses and BCG-induced in-vitro T cell
384	proliferation in SCH subjects with or without BCG vaccination

Variables		BCG scar absent	BCG scar present	P-value
		(n = 11)	(n = 53)	
Age (years)*		31.92±7.75	36.20±11.14	0.118
BMI (kg/m ²))*	22.15±2.81	26.34±5.82	0.030
TSH (µIU/ml)*		7.94±1.67	6.75±1.56	0.026
fT4(ng/dl)*		1.52±0.55	1.34±0.33	0.376
fT3(pmol/L)*		5.74±0.92	5.53±1.07	0.468
Anti – TPO Ab (IU/ml) [#]		12.0 (5-150)	16.4 (5-75)	0.913
Anti - TG Ab (IU/ml) [#]		56.0 (11-454)	106.9 (37.3-345.9)	0.516
Mantoux	Negative n (%)	5 (45.45)	28 (52.83)	0.663
Test	Positive n (%)	6 (54.55)	25 (47.17)	
Proliferation index (BCG)*		2.38±0.29	2.56±0.36	0.127

* Mean(\pm SD), the p-value was calculated by independent-samples t-test for parametric

variables. # Median (1st – 3rd quartile), the p-value was calculated by Mann Whitney U test

387 for continuous non-parametric data and Chi-square test for categorical data. Abbreviations:

388 BMI: Body mass index, BCG: Bacillus Calmette-Guerin, TSH: Thyroid stimulating hormone,

389 fT4: Free thyroxine, fT3: Free triiodothyronine, TG: Thyroglobulin, TPO: Thyroid

390 peroxidase, Ab: Antibody. The subjects with the presence of a BCG scar were considered as

391 BCG vaccinated.

392

394 **DISCUSSION**

Hashimoto's thyroiditis is primarily mediated by autoreactive T cells that induce the destruction of thyrocytes. BCG vaccine has been shown to have an immunomodulatory role in autoimmune diseases like T1DM, and MS [15,16,23], however, to the best of our knowledge, there is no human study on the role of BCG vaccination in HT or related autoimmune thyroid diseases. We included only SCH subjects and attempted to assess the effects of prior BCG vaccination on anti-thyroid immune responses and its impact during the early pathogenesis of the disease

402 Overall, most of the HT-SCH subjects were non-reactive to the Mantoux test as compared to 403 NA-SCH and HC subjects. Amongst the SCH subjects, the BCG-vaccinated group showed 404 lower levels of TSH in comparison to the non-vaccinated group. Additionally, those SCH 405 subjects retaining the efficacy of BCG had almost significantly lower titers of anti-TG 406 antibodies. Together, these observations indicate that the persistence of BCG efficacy has 407 some role in regulating autoimmune responses towards the thyroid gland. It is also pertinent 408 to mention here that the BCG scar may be absent in 1-20 % of subjects even after vaccination 409 [24,25]. There are a few reports where BCG vaccination has been shown to be associated 410 with a lower frequency of autoreactive T cells resulting in a decrease in the pathogenesis of 411 autoimmune diseases [14]. In the case of thyroid, in a mouse model of Graves' disease, 412 Nagayama et al. (2004), demonstrated that BCG vaccination slows disease progression by 413 diverting the anti-TSHR directed Th1 cells and reducing the production of anti-TSHR 414 antibodies [19]. In another study, GAD65 and IA-2 autoantibody titers were observed to be 415 lower in BCG-vaccinated (ascertained by the presence of a BCG scar) T1D subjects [26]. 416 Likewise, in our study, prior BCG vaccination was associated with lower levels of TSH in 417 SCH subjects.

418 In contrast to Mantoux reactivity, we did not find any difference between in-vitro BCG-419 induced PBMC proliferation in subjects in the context of their BCG vaccination status. We 420 think that there could be inherent potential differences between in-vivo and in-vitro responses 421 of T cells to BCG and this assay might not ascertain BCG vaccination efficacy, efficiently, 422 particularly in the Indian subcontinent due to the likelihood of prior exposure to 423 subclinical/environmental tuberculosis, non-tubercular infections. The absence of correlation 424 between in-vivo and in-vitro BCG-specific immune responses has been seen in similar 425 studies as well. Biswas et al. 1997 observed no correlation between Mantoux response and 426 PPD-induced lymphocyte proliferation in Eales' disease [27]. In another study, Arya et al. 427 (2018) observed that both healthcare workers and active tuberculosis patients had similar lymphocyte proliferation in response to Mycobacterium tuberculosis (MTB) Memory antigen 428 429 irrespective of their Mantoux test reactivity [28]. These findings suggest that 430 subclinical/environmental exposure to MTB in areas with a prevalence of tuberculosis 431 influences BCG-associated immune responses.

To study autoreactive T cells, various TPO peptides have been used previously [20]. We could demonstrate peripheral autoreactive CD8+ T cells recognizing, TPO-derived peptides

434 in both HT-SCH and NA-SCH subjects. The presence of autoreactive CD8+ T cells in NA-435 SCH could be attributed to higher levels of TSH, and without studying their phenotype it 436 would be too early to label these DMR+CD8+ T cells as pathogenic. A similar study reported 437 the presence of autoreactive CD8+ T cells recognizing TG and TPO epitopes in anti-TG and 438 anti-TPO antibody-negative subjects [21]. Therefore, these observations support the 439 occurrence of positive cellular immune responses even in the absence of humoral immune 440 responses toward thyroid antigens [20,21]. However, we cannot comment on whether this 441 could be attributed to the 'trained immunity' imparted by BCG, since we did not assess BCG 442 reactive T cells in these subjects.

443 Another relevant finding from our study was a positive correlation between TSH levels and 444 autoreactive CD8+T cells suggesting initiation of cellular autoimmunity leading to thyroid 445 parenchymal destruction before the onset of humoral responses. Similarly, Ehlers et al. 446 (2012) showed a lack of correlation between anti-TPO Ab and autoreactive CD8+ T cells 447 [20]. This varying correlation of anti-thyroid antibodies with autoreactive CD8+ T cells probably highlights the fact that autoreactive CD8+ T cells emerge earlier than the 448 449 autoantibody-producing B cells, which likely have a bystander or a surrogate role rather than being pathogenic [6,10,29]. Since cytotoxic CD8+ T cells primarily mediate damage to the 450 451 thyroid gland, their appearance in both HT-SCH and NA-SCH subjects is an indication that 452 the onset of hypothyroidism perhaps also initiates a phase of autoimmunity. However, a 453 smaller number of subjects available in the non-BCG vaccinated group, lack of objective 454 evidence of iodine sufficiency, and fine needle aspiration cytology (FNAC) of the thyroid 455 gland to confirm the diagnosis of autoimmunity are the main limiting factors in our study. 456 Nevertheless, this is the first human study ever done in HT subjects highlighting the 457 association between appearances of anti-thyroid autoimmunity in the context of BCG 458 vaccination.

459 Conclusions

460 In conclusion, our study highlighted a complex relationship between neonatal BCG 461 vaccination and the appearance of autoimmunity in the thyroid gland in SCH subjects. Our 462 results suggest that BCG vaccination has some influence on the genesis of HT by altering the 463 frequencies of autoreactive T cells and the appearance of antibodies directed toward thyroid 464 autoantigens. BCG is a time-tested safe vaccine that has already shown its non-specific 465 effects in other infections and autoimmune diseases. We have now partially demonstrated 466 that neonatal BCG vaccination exerts an immunomodulatory role on thyroid autoimmunity. 467 Our data warrants further long-term human studies in adult subjects with family history or 468 early onset of HT to assess the utility of BCG in therapeutic vaccination.

469 Acknowledgements

We acknowledge the technical staff of the Department of Endocrinology, PGIMER,Chandigarh, including Mr Vivek Sharma, Mudasir Hassen, Pintoo Kumar, Raj Davinder

- 472 Kaur for their support and assistance in performing all the laboratory investigations related to
- 473 this study.

474 Funding

This research did not receive any specific grant from any funding agency in public, commercial or not-for-profit sector.

477 **Conflict of Interest**

478 All the authors declare that they have no conflict of interest.

479

480 **REFERENCES**

- Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P: Autoimmune thyroid
 disorders. Autoimmun Rev. 2015, 14:174–80. 10.1016/j.autrev.2014.10.016
- 483 2. McLeod DSA, Cooper DS: The incidence and prevalence of thyroid autoimmunity.
 484 Endocrine. 2012, 42:252–65. 10.1007/s12020-012-9703-2
- 3. Deshmukh V, Behl A, Iyer V, Joshi H, Dholye JP, Varthakavi PK: Prevalence, clinical and
 biochemical profile of subclinical hypothyroidism in normal population in Mumbai.
 Indian J Endocrinol Metab. 2013, 17:454–9. 10.4103/2230-8210.111641
- 4. Unnikrishnan A, Bantwal G, John M, Kalra S, Sahay R, Tewari N: Prevalence of
 hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J
 Endocrinol Metab. 2013, 17:647. 10.4103/2230-8210.113755
- 491 5. Nyström E, Berg GEB, Jansson SKG, Tørring O, Valdemarsson SV: Thyroid Disease in
 492 Adults. Springer Berlin Heidelberg: Berlin, Heidelberg; 2011. 10.1007/978-3-642-13262493 9
- 494 6. Zaletel K, Gaberšček S: Hashimoto's Thyroiditis: From Genes to the Disease. Curr
 495 Genomics. 2011, 12:576–88. 10.2174/138920211798120763
- Frommer L, Kahaly GJ: Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic
 Link. Front Endocrinol. 2021, 12:618213. 10.3389/fendo.2021.618213
- Luty J, Ruckemann-Dziurdzińska K, Witkowski JM, Bryl E: Immunological aspects of
 autoimmune thyroid disease Complex interplay between cells and cytokines. Cytokine.
 2019, 116:128–33. 10.1016/j.cyto.2019.01.003
- 501 9. Li Q, Wang B, Mu K, Zhang J: The pathogenesis of thyroid autoimmune diseases: New T
 502 lymphocytes Cytokines circuits beyond the Th1–Th2 paradigm. J Cell Physiol. 2019,
 503 234:2204–16. 10.1002/jcp.27180

- 504 10. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ: Williams textbook of
 505 endocrinology. 14th ed. Elsevier, Inc: Philadelphia; 2019.
- 506 11. World Health Organization: BCG vaccine. WHO position paper. Releve Epidemiol Hebd.
 507 2004, 79:27–38.
- 508 12. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F:
 509 Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published
 510 literature. JAMA. 1994, 271:698–702.
- 511 13. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN: Impairment of Regulatory T-Cell
 512 Function in Autoimmune Thyroid Disease. Thyroid. 2013, 23:871–8.
 513 10.1089/thy.2012.0514
- 514 14. Faustman DL, Wang L, Okubo Y, et al.: Proof-of-Concept, Randomized, Controlled
 515 Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes.
 516 PLoS ONE. 2012, 7:e41756. 10.1371/journal.pone.0041756
- 517 15. Kühtreiber WM, Tran L, Kim T, et al.: Long-term reduction in hyperglycemia in advanced
 518 type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. Npj
 519 Vaccines. 2018, 3:. 10.1038/s41541-018-0062-8
- 16. Ristori G, Faustman D, Matarese G, Romano S, Salvetti M: Bridging the gap between
 vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases
 of type 1 diabetes and multiple sclerosis. Curr Opin Immunol. 2018, 55:89–96.
 10.1016/j.coi.2018.09.016
- 524 17. Dias HF, Kühtreiber WM, Nelson KJ, Ng NC, Zheng H, Faustman DL: Epigenetic changes
 525 related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for
 526 KDM2B. Vaccine. 2021, S0264410X21004461. 10.1016/j.vaccine.2021.04.011
- 18. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B: Schistosoma mansoni
 and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a
 mouse model of Graves' hyperthyroidism. J Immunol Baltim Md 1950. 2004, 173:2167–
 73.
- 19. Nagayama Y, McLachlan SM, Rapoport B, Oishi K: Graves' hyperthyroidism and the
 hygiene hypothesis in a mouse model. Endocrinology. 2004, 145:5075–9.
 10.1210/en.2004-0683
- 534 20. Ehlers M, Thiel A, Bernecker C, et al.: Evidence of a Combined Cytotoxic Thyroglobulin
 535 and Thyroperoxidase Epitope-Specific Cellular Immunity in Hashimoto's Thyroiditis. J
 536 Clin Endocrinol Metab. 2012, 97:1347–54. 10.1210/jc.2011-2178
- 537 21. Cai Y, Xu X, Zhang Z, et al.: Identification of novel HLA-A0201-restricted T-cell epitopes
 538 against thyroid antigens in autoimmune thyroid diseases. Endocrine. Published Online
 539 First: 20 March 2020. 10.1007/s12020-020-02264-x

540	22. McMurchy AN, Levings MK: Suppression assays with human T regulatory cells: A
541	technical guide: Highlights. Eur J Immunol. 2012, 42:27–34. 10.1002/eji.201141651
542	 Kowalewicz-Kulbat M, Locht C: BCG and protection against inflammatory and auto-
543	immune diseases. Expert Rev Vaccines. 2017, 16:699–708.
544	10.1080/14760584.2017.1333906
545	24. Dhanawade SS, Kumbhar SG, Gore AD, Patil VN: Scar formation and tuberculin
546	conversion following BCG vaccination in infants: A prospective cohort study. J Fam Med
547	Prim Care. 2015, 4:384–7. 10.4103/2249-4863.161327
548	25. Rani SH, Vijayalakshmi V, Sunil K, Lakshmi KA, Suman LG, Murthy KJ: Cell mediated
549	immunity in children with scar-failure following BCG vaccination. Indian Pediatr. 1998,
550	35:123–7.
551	26. Sanjeevi CB, Das AK, Shtauvere-Brameus A: BCG vaccination and GAD65 and IA-2
552	autoantibodies in autoimmune diabetes in southern India. Ann N Y Acad Sci. 2002,
553	958:293–6. 10.1111/j.1749-6632.2002.tb02990.x
554 555 556	27. Biswas J, Narain S, Roy S, Madhavan HN: Evaluation of lymphocyte proliferation assay to purified protein derivative, enzyme linked immunosorbant assay, and tuberculin hypersensitivity in Eales' disease. Indian J Ophthalmol. 1997, 45:93–7.
557	28. Arya S, Kumar SK, Nath A, Kapoor P, Aggarwal A, Misra R, Sinha S: Synergy between
558	tuberculin skin test and proliferative T cell responses to PPD or cell-membrane antigens
559	of Mycobacterium tuberculosis for detection of latent TB infection in a high disease-
560	burden setting. PLOS ONE. 2018, 13:e0204429. 10.1371/journal.pone.0204429
561 562	29. Stassi G, De Maria R: Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol. 2002, 2:195–204. 10.1038/nri750